These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1181309)

  • 21. Induction of mania by L-dopa in a nonbipolar patient.
    Harsch HH; Miller M; Young LD
    J Clin Psychopharmacol; 1985 Dec; 5(6):338-9. PubMed ID: 4066999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
    Goberman AM; Coelho C
    NeuroRehabilitation; 2002; 17(3):237-46. PubMed ID: 12237505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-dopa and frontal cognitive function in Parkinson's disease.
    Lange KW; Paul GM; Robbins TW; Marsden CD
    Adv Neurol; 1993; 60():475-8. PubMed ID: 8420173
    [No Abstract]   [Full Text] [Related]  

  • 26. [The deterioration of patients with parkinsonism treated with L-dopa].
    Guillard A
    Nouv Presse Med; 1975 Oct; 4(35):2503-6. PubMed ID: 1196872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [L-Dopa].
    Benoit P; Peutillot A
    Soins; 1985 Apr; (452):I-II. PubMed ID: 3848106
    [No Abstract]   [Full Text] [Related]  

  • 28. [L-dopa in the therapy of Parkinson's disease today].
    Piccinin GL; Piccirilli M; Morocutti C
    Clin Ter; 1982 Jan; 100(2):189-202. PubMed ID: 6764620
    [No Abstract]   [Full Text] [Related]  

  • 29. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 30. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
    Gilligan B; Hancock R
    Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [L-dopa-induced psychoses and their treatment with L-tryptophan].
    Demling J
    Fortschr Med; 1986 Apr; 104(17):360-2. PubMed ID: 3710403
    [No Abstract]   [Full Text] [Related]  

  • 34. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The sixth year after L-dopa: quality of life and insights derived.
    Boshes B; Arbit J; Dolkart M; Blonsky ER; Kovach JW
    Trans Am Neurol Assoc; 1975; 100():166-8. PubMed ID: 1226599
    [No Abstract]   [Full Text] [Related]  

  • 36. [Motor complications in Parkinson disease, in patients undergoing levodopa therapy].
    García de Yébenes J; García Urra D; Vázquez A
    Neurologia; 1989; 4(1):1-3. PubMed ID: 2631800
    [No Abstract]   [Full Text] [Related]  

  • 37. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R; Schneevoigt K
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract]   [Full Text] [Related]  

  • 38. [Diagnosis and course (under treatment) of Parkinson disease].
    Fénelon G
    Rev Prat; 1997 May; 47(10):1062-7. PubMed ID: 9208668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.